Key statistics
As of last trade Shanghai Junshi Biosciences Co Ltd (688180:SHH) traded at 25.14, 8.93% above its 52-week low of 23.08, set on Sep 24, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 25.01 |
---|---|
High | 25.57 |
Low | 24.92 |
Bid | 25.14 |
Offer | 25.15 |
Previous close | 30.59 |
Average volume | 7.22m |
---|---|
Shares outstanding | 985.69m |
Free float | 689.94m |
P/E (TTM) | -- |
Market cap | 25.67bn CNY |
EPS (TTM) | -1.83 CNY |
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Announcements
- Junshi Biosciences Announces Toripalimab Obtained Approval for Marketing in India and China’s Hong Kong SAR
- Junshi Biosciences Announces European Commission Approval for Marketing of Toripalimab
- Junshi Biosciences Announces 2024 Interim Financial Results and Provides Corporate Updates
- Junshi Biosciences Announces Acceptance of Supplemental New Drug Application for Toripalimab as First-Line Treatment of Unresectable/Metastatic Melanoma
- Junshi Biosciences Announces Positive Opinion from the European Medicines Agency’s CHMP For Toripalimab
- Junshi Biosciences Announces the Acceptance of the Supplemental New Drug Application for Toripalimab Combined with Bevacizumab for the First-Line Treatment of Advanced Hepatocellular Carcinoma
- Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Advanced TNBC
- Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Small Cell Lung Cancer
- Junshi Biosciences Announces Phase 3 Study of Toripalimab Combined with Bevacizumab for the First-line Treatment of Advanced Hepatocellular Carcinoma Meets Primary Endpoint
- Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab
More ▼